Scroll to top

Australian TGA commences SCENESSE® review

EXECUTIVE SUMMARY

  • SCENESSE® (afamelanotide 16mg) technology review starts in Australia for rare disease EPP
  • Priority Review aims at a technology review timeframe of 150 working days
  • Advisory Committee on Medicines may be required during the review of SCENESSE®

Download PDF

 

We use cookies to give you the best experience.